OBJECTIVE: To confirm the feasibility and safety of granulocyte colony-stimulating factor (G-CSF) for treating spinal neuropathic pain associated with compression myelopathy, we have initiated an open-label single-center prospective clinical trial. METHODS:Between January 2009 and February 2011, 17 patients were accrued and were divided into two groups. One group included 7 patients who complained of pain associated with worsening symptoms of myelopathy (progressing myelopathy-related pain group). The other group included 10 patients who complained of pain that persisted after surgery for compression myelopathy (post-operative persistent pain group). All patients underwent intravenous administration of G-CSF (10 μg/kg/day) for 5 consecutive days. Pain severity was evaluated using a visual analog scale (VAS) before and after G-CSF administration. RESULTS: In 14 of the 17 patients, pain was relieved within several days after G-CSF administration. Pain disappeared completely in 3 patients. In the progressing myelopathy-related pain group, the mean VAS score was 71.4/100 before G-CSF administration, and decreased to 35.9/100 at 1 week after G-CSF administration (p < 0.05). In the post-operative persistent pain group, the mean VAS score was 72.0/100 before G-CSF administration, and decreased to 51.7/100 at 1 week after G-CSF administration (p < 0.05). No severe adverse events occurred during or after G-CSF administration. CONCLUSIONS: The present results provide us with the possibility that G-CSF has a pain-relieving effect for neuropathic pain in patients with compression myelopathy.
RCT Entities:
OBJECTIVE: To confirm the feasibility and safety of granulocyte colony-stimulating factor (G-CSF) for treating spinal neuropathic pain associated with compression myelopathy, we have initiated an open-label single-center prospective clinical trial. METHODS: Between January 2009 and February 2011, 17 patients were accrued and were divided into two groups. One group included 7 patients who complained of pain associated with worsening symptoms of myelopathy (progressing myelopathy-related pain group). The other group included 10 patients who complained of pain that persisted after surgery for compression myelopathy (post-operative persistent pain group). All patients underwent intravenous administration of G-CSF (10 μg/kg/day) for 5 consecutive days. Pain severity was evaluated using a visual analog scale (VAS) before and after G-CSF administration. RESULTS: In 14 of the 17 patients, pain was relieved within several days after G-CSF administration. Pain disappeared completely in 3 patients. In the progressing myelopathy-related pain group, the mean VAS score was 71.4/100 before G-CSF administration, and decreased to 35.9/100 at 1 week after G-CSF administration (p < 0.05). In the post-operative persistent pain group, the mean VAS score was 72.0/100 before G-CSF administration, and decreased to 51.7/100 at 1 week after G-CSF administration (p < 0.05). No severe adverse events occurred during or after G-CSF administration. CONCLUSIONS: The present results provide us with the possibility that G-CSF has a pain-relieving effect for neuropathic pain in patients with compression myelopathy.
Authors: Claire L Gibson; Nigel C Jones; Malcolm J W Prior; Philip M W Bath; Sean P Murphy Journal: J Neuropathol Exp Neurol Date: 2005-09 Impact factor: 3.685
Authors: S Störmer; H J Gerner; W Grüninger; K Metzmacher; S Föllinger; C Wienke; W Aldinger; N Walker; M Zimmermann; V Paeslack Journal: Spinal Cord Date: 1997-07 Impact factor: 2.772
Authors: Diana D Cardenas; Catherine A Warms; Judith A Turner; Helen Marshall; Marvin M Brooke; John D Loeser Journal: Pain Date: 2002-04 Impact factor: 6.961
Authors: Dorota Sienkiewicz; Wojciech Kułak; Bożena Okurowska-Zawada; Grażyna Paszko-Patej; Janusz Wojtkowski; Karolina Sochoń; Anna Kalinowska; Kamila Okulczyk; Jerzy Sienkiewicz; Edward McEachern Journal: Front Neurol Date: 2017-10-26 Impact factor: 4.003